Published in final edited form as:

Expert Opin Emerg Drugs. 2011 December ; 16(4): 597–602. doi:10.1517/14728214.2011.644786.

Emerging adenosine receptor agonists—an update

Zhan-Guo Gao¹ and Kenneth A Jacobson²

Zhan-Guo Gao: zg21o@nih.gov; Kenneth A Jacobson: kajacobs@helix.nih.gov

¹Staff Scientist, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bldg. 8A, Room B1A-23, 9000 Rockville Pike, Bethesda, Maryland 20892-0810, USA. Fax: +1 301 480 8422

²Chief, Laboratory of Bioorganic Chemistry & Molecular Recognition Section, NIDDK, National Institutes of Health, , Bldg. 8A, Room B1A-19, 9000 Rockville Pike, Bethesda, Maryland 20892-0810, USA. Fax: +1 301 480 8422

Abstract

Adenosine receptors (ARs), the major targets of caffeine and theophylline, comprise four receptor subtypes designated as A₁, A_{2A}, A_{2B} and A₃. Over a dozen AR agonists are currently in clinical trials for various conditions, including cardiac arrhythmias, neuropathic pain, myocardial perfusion imaging, cardiac ischemia, inflammatory diseases and cancer. Adenosine (non-selective), regadenoson (A_{2A}) and dipyridamole (act indirectly via ARs) have received regulatory approval for clinical use. The present editorial will give a brief update on the current status of AR agonists in clinical trials.

Keywords

adenosine receptor; agonist; cardiac arrhythmia; cardiac perfusion imaging; cancer; G protein-coupled receptor; inflammation; nucleoside; pain; rheumatoid arthritis

1. Introduction

Adenosine, a naturally occurring nucleoside, is the endogenous agonist of four members of G protein-coupled receptors, A₁, A_{2A}, A_{2B} and A₃ adenosine receptors (ARs) [1,2,3]. AR antagonism is the major mechanism of action at ingested doses of the alkylxanthines caffeine and theophylline, the most widely consumed drugs in the world.

Adenosine has a general cytoprotective function as a response to organ stress, such as hypoxia. There is growing evidence that AR agonists are attractive therapeutic targets for a number of conditions, including pain, cardiac arrhythmias, myocardial perfusion imaging, cardiac ischemia, inflammation and certain types of cancer [4–9]. An increasing number of AR agonists are currently in clinical trials, and some have received regulatory approval.

The development of AR agonists as drugs has been limited in the past by the essential requirement of the retention of the ribose moiety of adenosine for agonist activity. However, non-nucleoside AR agonists are now also in development [1–3]. The present article will briefly recapitulate the rationale behind the development and briefly review the current status of AR agonists in clinical trials for various conditions. This Editorial is an update of

Declaration of interest:

The authors and this paper were supported by NIDDK Intramural Research, National Institutes of Health. The authors declare no other conflicts of interest.

the review published 5 years ago in the same journal [1] (*Expert Opinion on Emerging Drugs*, 12, 479, 2007).

2. Current status of adenosine receptor agonists in clinical trials for various conditions

2.1. Cardiac arrhythmias

The first reported biological actions of adenosine are its depressant effect on heart rate and atrioventricular (AV) conduction [1–3]. This knowledge has continuously fueled considerable interest in pursuing AR agonists as drugs for cardiac arrhythmias, including atrial fibrillation (AF), supraventricular arrhythmias, paroxysmal supraventricular tachycardia (PSVT) and atrial flutter. Adenosine has been approved for PSVT under the name Adenocard, the effect of which is mediated via the A₁AR, which is known to be abundant in the AV node of the heart. However, adenosine is a nonselective AR agonist, the adverse effects of which, such as flushing, dyspnea, chest discomfort and hypotension, are through the activation of other AR subtypes. Thus, there has been interest to develop more selective A₁AR agonists having fewer side effects.

Tecadenoson (CVT-510), a full agonist for the A₁AR, is in Phase III trial for patients with PSVT, AF and atrial flutter. It appears that low doses of Tecadenoson have minimal effects on AV nodal conduction and blood pressure compared with adenosine. However, at high doses, like other full agonists for the A₁AR, it may also display AV block. A Phase II clinical trial of another full A₁AR agonist, Selodenoson, for AF has also been successfully completed. Both agonists showed promising therapeutic efficacy. However, their progress for further development will probably depend on potential side effects. A Phase II trial of BAY 68-4986 (Capadenoson), a non-nucleoside A₁AR agonist, in patients with persistent or permanent AF has been completed. This represents a novel chemotype among AR agonists for clinical development. A clinical trial of Capadenoson for angina was withdrawn [10].

2.2. Pain

The A₁AR is abundantly expressed in spinal cord and other neuronal tissues. A₁AR activation produced pain-relieving effects in a number of preclinical animal models [4]. Adenosine is currently in Phase II trials for patients with perioperative pain and neuropathic pain. Selective A₁AR agonists are being developed as analgesics. However, it seems that several A₁AR agonists, SDZ WAG 994, GR79236 and GW- 493838, and one A₁AR allosteric enhancer T62 [11], have been withdrawn, possibly due to fact that these drugs may not penetrate the CNS sufficiently to cause a substantial effect. Also, high doses may also produce adverse effects, as A₁AR is abundant in a number of tissues including CNS, heart and adipose tissues. It has been suggested that partial agonists for the A₁AR have the potential to produce a selective targeted response avoiding cardiovascular effects [12]. Thus, partial A₁AR agonists or biased A₁AR agonists, i.e. selective for certain signaling pathways, may be needed, in addition to those of increased A₁AR selectivity, for further development.

A Phase II trial of the efficacy and tolerability of a novel A_{2A}AR agonist BVT.115959 in the treatment of diabetic neuropathic pain has been completed in 2008, but there has not been an update since then.

2.3. Diabetes

Type 2 diabetes (T2D) patients have increased levels of non-esterified fatty acids (NEFA) in part due to β -adrenergic agonism, which decrease insulin sensitivity [3,13]. Thus, lowering NEFA levels has an insulin-sensitizing effect. A full A₁AR agonist, GR79236, has been in clinical trial for T2D but failed due to cardiovascular side effects. Partial A₁AR agonists

might lower NEFA levels without cardiovascular or CNS side effects. Gilead Sciences initiated a Phase I trial of CVT-3619 (GS9667), a partial A_1 AR agonist, for T2D in 2008. This Phase I, single-blind, placebo-controlled, single ascending dose study evaluated the safety, tolerability and pharmacokinetics of oral CVT-3619, in 55 healthy and 23 obese volunteers. No clinically meaningful changes in heart rate or blood pressure were observed in the study, suggesting that CVT-3619 may increase insulin sensitivity and subsequently decrease blood glucose via lowering NEFA level without causing severe cardiovascular effects.

2.4. Myocardial perfusion imaging

The vasodilatory effect of the non-selective and short-acting agonist, adenosine, is mainly mediated via the A_{2A} AR, which is abundant in the coronary blood vessels [1,2,3]. Adenosine, under the name Adenoscan is approved for myocardial perfusion imaging. In addition to its vasodilatory effect, adenosine may act at other ARs to induce side effects, e.g. action on the A_1 AR may cause AV-block and action on the A_{2B} AR may induce bronchospasm especially in patients with asthma. Thus, selective A_{2A} AR agonists are needed to replace adenosine.

Three synthetic A_{2A} AR agonists, Regadenoson, Binodenoson, Apadenoson are being applied to myocardial perfusion imaging, and Regadenoson has received regulatory approval under the name of Lexiscan. The other two agonists are still waiting for approval. Dipyridamole (Persantine), which indirectly activates the A_{2A} AR through increasing the concentration of adenosine as a nucleoside transporter inhibitor, is still being used for myocardial perfusion imaging.

2.5. Cardioprotection

All four ARs have been reported to be cardioprotective via various mechanisms. Phase II clinical trial of adenosine preconditioning in myocardial protection has been completed. A clinical trial with adenosine for acute myocardial infarction is now in Phase III [10]. In addition to adenosine, the nucleoside transporter inhibitor, dipyridamole, as an indirect AR agonist, has long been used in clinic for heart attack and stroke and is still in clinical trial for protection against ischemia-reperfusion injury [10]. The selective, non-nucleoside A_{2B} AR agonist, Bay 60-6583, has been shown to provide protection from ischemia in animal models and it has been proposed for use in drug-eluting stents [14,15].

The recent demonstration of the cardioprotective effect of the A_3 AR with a positive allosteric modulator, LUF6096, further highlighted the broad therapeutic potential of A_3 AR activation [16,17].

2.6. Inflammatory diseases

Activation of A_{2A} , A_{2B} and A_3 ARs is known to have anti-inflammatory effects in part due to inhibition of the release of proinflammatory cytokines. Agonists for both A_{2A} and A_{2B} ARs might be useful treatment of intestinal inflammation [18]. The anti-inflammatory role of the A_{2A} AR has been extensively studied and confirmed in multiple animal models. However, the pro- or anti-inflammatory roles of both A_{2B} and A_3 ARs are still controversial [5,6,7,8,19].

A possible therapeutic role for adenosine during inflammation is being studied clinically [10]. A clinical trial regarding the role of adenosine in the release of vascular endothelial growth factor (VEGF) and cytokines has been suspended (to be re-evaluated). Adenosine has been in clinical trial for perioperative pain, presumably due to its anti-inflammatory properties which may contribute to pain relief in the peripheral setting of inflammation. A

Phase IV trial of the effects of oral dipyridamole treatment on the innate immune response during human endotoxemia has been completed [10], but clinical data are not available.

An A_{2A}AR agonist, Sonedenoson, is in clinical trial as an experimental topical drug for the treatment of chronic, neuropathic, diabetic foot ulcers due to its wound healing and anti-inflammatory effect. The beneficial effect of the A_{2A}AR agonist BVT.115959 in treatment of diabetic neuropathic pain is also due to its anti-inflammatory effect. Regadenoson, the A_{2A}AR agonist approved for myocardial perfusion imaging, is in trials in children and adults with sickle cell disease due to its anti-inflammatory effect [10].

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. Although the pathogenesis of RA is still largely unclear, it appears to be an autoimmune disease driven by activated T cells, with increased T cell-derived cytokines. Although a number of cyclooxygenase inhibitors (aspirin, ibuprofen and diclofenac) are in clinical use, their therapeutic effects are often uncertain, and gastric and intestinal side effects are common. The A_{2A}AR has long been proposed to be a target for the treatment of arthritis, but there have been no agonists reported in clinical trial principally for RA. Nevertheless, investigators are evaluating the effects of undisclosed A_{2A}AR agonists on atherogenic parameters in plasma of Systemic Lupus Erythematosus and RA patients, based on the anti-inflammatory action of the A_{2A}AR [10]. Dipyridamole alone or in combination with prednisolone for patients with moderate to severe RA is in Phase II clinical trial. The A₃AR agonist CF101 (IB-MECA) is currently in a Phase II trial for patients with RA via oral administration. Oral CF101 is also in trials for patients with psoriasis and dry eye disease, for which Phase II results showed significant improvement, and with glaucoma [9].

2.7. Cancer

ARs are involved in cell proliferation, apoptosis, metastasis and angiogenesis, suggesting their role in cancer [1,2,3,9]. AR agonists that induce apoptosis or inhibit proliferation, metastasis and angiogenesis may potentially have anti-cancer effect. Clinical trial of CF102, an A₃AR agonist, in patients with advanced hepatocellular carcinoma is on-going. A Phase 1/2 study of CF102 in patients with chronic hepatitis C genotype 1 has been completed. The indirect AR agonist dipyridamole in trials together other anticancer drugs for patients with stage II or stage III pancreatic cancer and advanced ovarian cancer [10]. 8-Chloroadenosine, which is only weakly acting at ARs, is in a Phase I trial for patients with chronic lymphocytic leukemia.

In addition to the indications mentioned above, dipyridamole has been used clinically for other conditions related to the indirect activation of ARs and is currently still in extensive clinical trials for various conditions either alone or in combined therapy. For example, the therapeutic effect of dipyridamole is being compared with that of olanzapine in schizophrenia patients; Dipyridamole is also in a Phase II clinical trial for anemia. If the positive effect is identified and the AR subtypes involved in dipyridamole's effect are defined, selective AR agonists could be further developed for those conditions.

3. Summary

Considerable efforts have been put in the development of AR agonists for various conditions, and one synthetic A_{2A}AR agonist, Regadenoson, has received approval for myocardial perfusion imaging. A number of full A₁AR agonists have failed in the trials for some conditions in recent years due to their side effects. Partial agonists, biased agonists or allosteric enhancers for the A₁AR which may produce selective targeted response could be further developed. The development of the selective A_{2B}AR agonists for various conditions still lags behind the other subtypes. Two A₃AR agonists are being developed for a number

of conditions. The recently synthesized A₃AR allosteric enhancers could be further explored for a number of conditions, such as inflammation, cancer and cardiac ischemia. With the availability of the agonist-bound AR crystal structure [20], it is hoped that more selective or biased AR agonists will be rationally designed and developed. As mentioned earlier, caffeine and theophylline are AR antagonists; thus, limiting the intake of coffee and tea is necessary when AR agonists are administered. It is predicted that there will be more AR agonists receiving regulatory approval for various conditions in the near future.

List of abbreviations

AR	adenosine receptor
MPI	myocardial perfusion imaging
AF	atrial fibrillation
PSVT	paroxysmal supraventricular tachycardia
NEFA	non-esterified fatty acids
RA	rheumatoid arthritis
AV	atrioventricular

References

1. Gao ZG, Jacobson KA. Emerging adenosine receptor agonists. *Expert Opin Emerg Drugs*. 2007 Sep; 12(3):479–92. [PubMed: 17874974]
2. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. *Pharmacol Rev*. 2011 Mar; 63(1):1–34. [PubMed: 21303899]
3. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. *Nat Rev Drug Discov*. 2006 Mar; 5(3):247–64. [PubMed: 16518376]
4. Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. *Expert Opin Investig Drugs*. 2008 Dec; 17(12):1901–10.
5. Cristalli G, Müller CE, Volpini R. Recent developments in adenosine A2A receptor ligands. *Handb Exp Pharmacol*. 2009; (193):59–98. [PubMed: 19639279]
6. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat Rev Drug Discov*. 2008 Sep; 7(9):759–70. [PubMed: 18758473]
7. Koeppen M, Eckle T, Eltzschig HK. Interplay of hypoxia and A2B adenosine receptors in tissue protection. *Adv Pharmacol*. 2011; 61:145–86. [PubMed: 21586359]
8. Feoktistov I, Biaggioni I. Role of adenosine A2B receptors in inflammation. *Adv Pharmacol*. 2011; 61:115–44. [PubMed: 21586358]
9. Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A₃ adenosine receptor agonists. *Drug Discov Today*. in press.
10. 101. Clinicaltrials.gov
11. Romagnoli R, Baraldi PG, Tabrizi MA, Gessi S, Borea PA, Merighi S. Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development. *Curr Med Chem*. 2010; 17(30):3488–502. [PubMed: 20738250]
12. Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli L. Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. *J Pharmacol Exp Ther*. 2007; 321(1):327–33. [PubMed: 17204748]
13. Delarue J, Magnan C. Free fatty acids and insulin resistance. *Curr Opin Clin Nutr Metab Care*. 2007; 10(2):142–8. [PubMed: 17285001]

14. Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK. Cardioprotection by ecto-5'-nucleotidase (CD73) and A_{2B} adenosine receptors. *Circulation*. 2007; 115(12):1581–90. [PubMed: 17353435]
15. Drug-eluting stents for adenosine receptor modulation. United States Patent Application. 20110189255.
16. Du L, Gao ZG, Nithipatikom K, IJzerman AP, van Veldhoven JP, Jacobson KA, Gross GJ, Auchampach JA. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. *J Pharmacol Exp Ther*. 2011 Oct 21. [Epub ahead of print].
17. Gao ZG, Verzijl D, Zweemer A, Ye K, Göblyös A, IJzerman AP, Jacobson KA. Functionally biased modulation of A₃ adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. *Biochem Pharmacol*. 2011 Sep 15; 82(6):658–68. [PubMed: 21718691]
18. Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Del Tacca M, Blandizzi C. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. *Pharmacol Ther*. 2008 Dec; 120(3):233–53. Epub 2008 Sep 14. Review. [PubMed: 18848843]
19. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A₃ adenosine receptor: an enigmatic player in cell biology. *Pharmacol Ther*. 2008 Jan; 117(1):123–40. Epub 2007 Sep 22. Review. [PubMed: 18029023]
20. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC. Structure of an agonist-bound human A_{2A} adenosine receptor. *Science*. 2011; 332(6027):322–7. [PubMed: 21393508]

Question for the authors

- Please check your references carefully as they have been renumbered.
- Please cite your table and figure in the text.

Fig 1.
Structures of AR agonists currently in clinical trial.

Table 1

AR agonists in clinical trials.

Compound	Target AR	Company	Indication (phase)
Adenocard (Adenosine)	A ₁	Astellas	PSVT (approved)
Adenoscan (Adenosine)	A _{2A}	Astellas	MPI (approved)
Adenosine	ARs	Wake Forest Univ.	Neuropathic Pain (II)
		Xsira Pharma.	Perioperative Pain (II)
		Univ. North Norway	Angina Pectoris (I-II)
		Radboud Univ.	Cardiac Ischemia (IV)
		Univ. Maryland,	Schizophrenia
		Zalicus	Reumatoid arthritis (II)
		Ottawa/NCI	Ovarian Cancer (II).
		Southwest Oncol/NCI	Pancreatic Cancer (II)
		Boehringer Ingelheim	MPI (approved)
Dipyridamole (Persantine)	ARs (indirect)	Boehringer Ingelheim	Heart attack,stroke(approved)
Capadenoson (Bay68-4986)	A ₁	Bayer-Schering	AF (II)
Selodenoson (DTI0009)	A ₁	Astellas/Aderis	PSVT (II)
Tecadenoson (CVT510)	A ₁	Gilead	PSVT (III)
GS9667 (CVT-3619)	A ₁	Gilead	Diabetes (I)
INO-8875	A ₁	Inotek	Glaucoma (I-II)
Apadenoson (ATL146e)	A _{2A}	Forest Lab.	MPI (III)
Bidenoson (WRC0470)	A _{2A}	UCB (Aderis)	MPI (III)
Regadenoson (Lexiscan)	A _{2A}	Gilead/Astellas	MPI (approved)
		Dana-Farber	Sickle cell disease (I)
BVT.115959	A _{2A}	Biovitrium	Diabetic neuropathic pain (II)
Sonedenoson (MRE0094)	A _{2A}	Pfizer	Diabetic foot ulcer (II)
Bay60-6583	A _{2B}	Bayer-Schering	not disclosed
CF101 (IB-MECA)	A ₃	Can-Fite	Psoriasis (II-III)
			Rheumatoid Arthritis (II)
			Dry eye disease (III)
			Glaucoma (II)
CF102 (CI-IB-MECA)	A ₃	Can-Fite	Liver cancer (I-II)
			Hepatitis (I-II)

MPI, myocardial perfusion imaging; AF, atrial fibrillation; PSVT, paroxysmal supraventricular tachycardia